A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

Summary

We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent.

Timeline

Start

2013-12

Primary completion

2014-12

Completion

2015-07

Drugs

Indications